Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2044

Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.

Patents
1,766

Quick answer

1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12016948

    Micromotors and nanomotors for gastrointestinal diagnosis and treatment applications

    The Regents of the University of California · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12016860

    Combination therapies with Cbl-b inhibitor compounds

    NURIX THERAPEUTICS, INC. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12016835

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12016950

    Devices and methods for treating ear pain

    Try This First, Inc. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12017989

    Controlled release pharmaceutical formulations

    United Therapeutics Corporation · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12018001

    Pyrimidine cyclohexenyl glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12018011

    Macrocyclic compounds and compositions, and methods of preparing and using the same

    Kura Oncology, Inc. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12017030

    Hydrogen-enhanced transdermal system

    H2 Universe LLC · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12018027

    Macrocyclic derivatives acting as XIa factor inhibitor

    China Resources Biopharmaceutical Company Limited · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12018043

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12018057

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12018052

    Methods of detection and removal of rhabdoviruses from cell lines

    Takeda Vaccines, Inc. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12018090

    PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12018125

    Block-copolymers for the delivery of active agents

    Julius-Maximilians-Universitat Wurzburg · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12018135

    Encapsulation by cross-linking of anionic polymers by pH induced dissociation of cation-chelate complexes

    The Regents of the University of California · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. WO 2024133935

    EXCIPIENTS DE CONJUGAISON PROTÉIQUES

    ABLYNX NV [BE] · Granted Thu Jun 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12023337

    Methods of treating cancer

    Corvus Pharmaceuticals, Inc. · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12024486

    Lipocationic dendrimers and uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12023389

    Compositions that target tumor-associated macrophages and methods of use therefor

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12023335

    Method for treating pancreatic cancer

    PTC THERAPEUTICS, INC. · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12024512

    Cocrystal

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12023348

    EGR1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12023394

    Vesicle-coated fibers made from crosslinked lipids

    The Regents of the University of California · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12023383

    Lipid compositions

    ARBUTUS BIOPHARMA CORPORATION · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12023388

    Detection and treatment of caries and microcavities with nanoparticles

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12023355

    Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12025615

    Methods of classifying response to immunotherapy for cancer

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12024718

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12024570

    Anti-CTLA-4 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12024505

    Heterocyclic compounds useful as modulators of acetylcholine receptors

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12023343

    Thermo-kinetic mixing for pharmaceutical applications

    The Board of Regents of the University of Texas System · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12024556

    Anti-Staphylococcus antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12024509

    Therapeutic compounds as inhibitors of the orexin-1 receptor

    C4X Discovery Limited · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12023410

    Micro/nanobubble solutions for tissue preservation and generation thereof

    The Regents of the University of California · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12023391

    Alpha(v)beta(6) integrin-binding peptides and methods of use thereof

    The Regents of the University of California · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12023359

    Phospholipid compositions for delivery of therapeutic compounds

    Aker BioMarine Human Ingredients AS · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12023309

    Enhanced delivery epinephrine compositions

    Aquestive Therapeutics, Inc. · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. WO 2024141977

    CELLULES TUEUSES NATURELLES MODIFIÉES ET PROCÉDÉS ASSOCIÉS

    ASTELLAS PHARMA INC [JP] · Granted Thu Jul 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12031133

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12031147

    Adeno-associated virus virions with variant capsids and methods of use thereof

    The Regents of the University of California · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12029745

    Effects of LGM2605 on a primate model of asthma

    The Regents of the University of California · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12031157

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12031130

    Composition for modifying target gene

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12031136

    Treatment for skeletal diseases caused by intracellular protein trafficking defects

    The Board of Regents of the University of Oklahoma · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12030970

    Curable composition and stereolithographic resin composition comprising same

    KURARAY CO., LTD. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12030925

    Methods of treating hemophilia A

    BIOVERATIV THERAPEUTICS INC. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12030940

    Immunotherapeutic tumor treatment method

    Nektar Therapeutics · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12030863

    Prodrugs of urolithins and uses thereof

    Amazentis SA · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2044?

1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.